单位:[1]Cardiovascular Center of Excellence, LSU Healther Science Center, 533 Bolivar St, New Orleans, LA 70112, USA.[2]Division of Cardiology,Department of Internal Medicine,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,1095 Jiefang Ave,Wuhan,430030,China.华中科技大学同济医学院附属同济医院大内科内科学系心血管内科
The nuclear receptor peroxisome proliferator-activated receptor δ (PPARδ) can transcriptionally regulate target genes. PPARδ exerts essential regulatory functions in the heart, which requires constant energy supply. PPARδ plays a key role in energy metabolism, controlling not only fatty acid (FA) and glucose oxidation, but also redox homeostasis, mitochondrial biogenesis, inflammation, and cardiomyocyte proliferation. PPARδ signaling is impaired in the heart under various pathological conditions, such as pathological cardiac hypertrophy, myocardial ischemia/reperfusion, doxorubicin cardiotoxicity and diabetic cardiomyopathy. PPARδ deficiency in the heart leads to cardiac dysfunction, myocardial lipid accumulation, cardiac hypertrophy/remodeling and heart failure. This article provides an up-today overview of this research area and discusses the role of PPARδ in the heart in light of the complex mechanisms of its transcriptional regulation and its potential as a translatable therapeutic target for the treatment of cardiac disorders.
语种:
外文
PubmedID:
第一作者:
第一作者单位:[1]Cardiovascular Center of Excellence, LSU Healther Science Center, 533 Bolivar St, New Orleans, LA 70112, USA.
推荐引用方式(GB/T 7714):
Yang Qinglin,Long Qinqiang.PPARδ, a Potential Therapeutic Target for Heart Disease.[J].Nuclear receptor research.2018,5:doi:10.32527/2018/101375.
APA:
Yang Qinglin&Long Qinqiang.(2018).PPARδ, a Potential Therapeutic Target for Heart Disease..Nuclear receptor research,5,
MLA:
Yang Qinglin,et al."PPARδ, a Potential Therapeutic Target for Heart Disease.".Nuclear receptor research 5.(2018)